NextCure (NXTC) Total Non-Current Liabilities (2021 - 2026)
NextCure (NXTC) posted quarterly Total Non-Current Liabilities of $10.8 million for Q1 2026, up 1.1% year-over-year from $10.7 million in Q1 2025, and down 26.8% quarter-over-quarter from $14.7 million in Q4 2025.
NextCure (NXTC) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
NextCure's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $10.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 1.1% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 1.1% YoY), while the FY2025 annual figure was $14.7 million, changed 0.09% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $10.8 million, down from $14.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $16.4 million in Q2 2024, with the low at $10.7 million in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $14.4 million (2023), against an average of $14.0 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 138.08% in 2022, then sank 30.63% in 2025.
- NextCure's Total Non-Current Liabilities stood at $15.7 million in 2022, then dropped by 18.43% to $12.8 million in 2023, then rose by 14.77% to $14.7 million in 2024, then dropped by 0.09% to $14.7 million in 2025, then fell by 26.8% to $10.8 million in 2026.
- Business Quant data shows NXTC's Total Non-Current Liabilities at $10.8 million in Q1 2026, $14.7 million in Q4 2025, and $15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.02 Mn |
| Mar 31, 2026 | 10.77 Mn |
| Dec 31, 2025 | 14.71 Mn |
| Sep 30, 2025 | 15.41 Mn |
| Jun 30, 2025 | 15.45 Mn |
| Mar 31, 2025 | 10.65 Mn |
| Dec 31, 2024 | 14.73 Mn |
| Sep 30, 2024 | 14.06 Mn |
| Jun 30, 2024 | 16.42 Mn |
| Mar 31, 2024 | 15.36 Mn |
| Dec 31, 2023 | 12.83 Mn |
| Sep 30, 2023 | 12.67 Mn |
| Jun 30, 2023 | 14.11 Mn |
| Mar 31, 2023 | 12.72 Mn |
| Dec 31, 2022 | 15.73 Mn |
| Dec 31, 2021 | 6.61 Mn |